Rohto to begin stem cell clinical test for COVID-19 in August

Rohto Pharmaceutical Co. said Tuesday it will begin a clinical trial in August using stem cells for a potential treatment for patients severely ill with COVID-19.The Osaka-based drugmaker said it will be the first time in Japan that domestic stem cells have been used for such a clinical test.To confirm the effectiveness and safety of this therapeutic approach, it will administer mesenchymal stem cells derived from adipose tissue from a donor to patients with severe cases of COVID-19, the respiratory disease caused by the novel coronavirus.The trial is expected to run through December but if…READ FULL ARTICLE